Jakobs F, Ahmadi P, Osterkamp V, Jeck J, Holtick U, Scheid C, Kron Florian
Department of Hematology and Stem Cell Transplantation, University Hospital Essen, Essen, Germany.
Department of Medical Psychology, University Hospital of Hamburg, Hamburg, Germany.
Cost Eff Resour Alloc. 2025 Mar 5;23(1):6. doi: 10.1186/s12962-024-00600-w.
Renal insufficiency is one of the most common complications in the treatment of multiple myeloma (MM). The administration of isatuximab showed improved patient outcome regarding the occurrence of renal insufficiency. Building on the results of the ICARIA-MM study, the aim of this study was to quantify the potential cost savings due to a prevented progress of renal insufficiency.
Real-life accounting data of the University Hospital Cologne (Germany) of inpatients with MM between 2016 and 2020 were analyzed regarding the presence of renal insufficiency. The health-economic impact of a less severe renal insufficiency due to improved renal filtration on German Diagnosis-Related Groups (G-DRG) tariffs was modelled.
The analysis revealed a total of 74 hospital cases with MM. The vast majority (n = 64; 86.5%) were allocated to the G-DRG code R61, summarizing patients with "lymphoma and non-acute leukemia". Based on a reduction of stage 3 renal failure to stage 2, the model showed cost saving potential in patients with acute renal failure ranging from € 3,101 to € 4,642 per case.
The analysis quantifies for the first time the economic saving potential of improved renal function in patients with relapsed/refractory multiple myeloma in the German healthcare system through the administration of isatuximab.
肾功能不全是多发性骨髓瘤（MM）治疗中最常见的并发症之一。isatuximab的使用在肾功能不全的发生方面显示出改善的患者预后。基于ICARIA-MM研究的结果，本研究的目的是量化由于预防肾功能不全进展而可能节省的成本。
分析了德国科隆大学医院2016年至2020年MM住院患者的实际会计数据，以了解肾功能不全的情况。对由于改善肾滤过导致的较轻肾功能不全对德国诊断相关组（G-DRG）费率的健康经济影响进行了建模。
分析共发现74例MM住院病例。绝大多数（n = 64；86.5%）被分配到G-DRG编码R61，该编码汇总了“淋巴瘤和非急性白血病”患者。基于将3期肾衰竭降至2期，该模型显示急性肾衰竭患者每例节省成本的潜力为3101欧元至4642欧元。
该分析首次量化了在德国医疗保健系统中，通过使用isatuximab改善复发/难治性多发性骨髓瘤患者肾功能所带来的经济节省潜力。
